IMCR — Immunocore Holdings plc

Nasdaq · Health Care · Biotechnology · CIK 1671927 ·
Last close
$28.96
Market Cap
$1.47B
52W High
$32.83
52W Low
$27.56
ADV30
379,910
Next earnings
2026-08-06
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 106,677,000 106,243,000 7,280,000 12,971,000 1,072,095,000 452,675,000 678,422,000
Dec 2025 104,478,000 101,775,000 -19,691,000 -30,060,000 1,067,269,000 467,709,000 686,236,000
Sep 2025 103,693,000 103,180,000 -7,171,000 -177,000 1,102,500,000 498,413,000 705,936,000
Jun 2025 97,964,000 96,924,000 -14,875,000 -10,300,000 1,082,387,000 487,933,000 693,906,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-10,712,000
Investing CF
$-16,340,000
Financing CF
$12,371,000
CapEx
$-4,340,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.70
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-831,275,000
Inventory
$6,742,000
Receivables
$101,121,000
ST Investments
$396,444,000
EBIT TTM
$-6,425,000
Pretax Income TTM
$-19,100,000
Interest Exp TTM
$12,675,000
Analysts
13

Yahoo Snapshot (yfinance, live)

Total Revenue
$412,812,000
EBITDA
$-11,369,000
Free Cash Flow
$58,577,376
Enterprise Value
$1,063,854,016
Total Cash
$844,896,000
Total Debt
$435,683,008
Shares Out
50,865,574
Trailing EPS
$-0.56
Book Value
$7.75
ROE
-7.1%
ROA
-0.9%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 400,016,000 -45,353,000 -35,514,000 1,067,269,000 686,236,000 -10,712,000
Dec 2024 310,202,000 -70,461,000 -51,087,000 1,009,506,000 648,790,000 26,061,000
Dec 2023 249,428,000 -59,649,000 -55,287,000 597,001,000 228,158,000 2,940,000
Dec 2022 174,361,000 -51,708,000 -52,543,000 526,762,000 187,859,000 -49,209,000

TTM Snapshot

Revenues TTM
$145,098,000
NetIncome TTM
$9,642,000
OpCashFlow TTM
$0
Assets (Latest)
$1,009,506,000
Forward EPS
$-0.67

Peers — same industry

TickerNameMarket CapLastDaily %
NVAX NOVAVAX INC $1.46B $8.88
VIR Vir Biotechnology, Inc. $1.45B $8.61
GLUE Monte Rosa Therapeutics, Inc. $1.54B $18.24
INBX Inhibrx Biosciences, Inc. $1.35B $92.20
MAZE Maze Therapeutics, Inc. $1.33B $24.05

News headlines (Yahoo Finance, 1h cache)

Sanofi Wins FDA Nod for Expanded Use of T1D Drug in Children
2026-06-15 16:12 · Yahoo
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
2026-06-15 14:43 · Yahoo
INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026
2026-06-12 14:20 · Yahoo
Is Indivior Stock a Buy After Higher 2026 Guidance?
2026-06-12 14:15 · Yahoo
INDV Stock: What Sublocade Growth Signals for 2026
2026-06-12 14:13 · Yahoo
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
2026-06-12 14:08 · Yahoo
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
2026-06-12 13:48 · Yahoo
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG
2026-06-10 13:17 · Yahoo
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results
2026-06-10 13:05 · Yahoo
ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know
2026-06-10 12:09 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.